关于儿科药物遗传学的最新情况
Irene Taladriz-Sender1, Sara Salvador-Martín1, Paula Zapata-Cobo1
1Servicio de Farmacia, Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM). Madrid, Spain.
Anales de pediatria
|January 14, 2026
概括
西班牙的药物遗传学应用正在增长,但在儿童中有限. 本综述分析了现有的儿科药物遗传学数据,突出了在儿童中更安全的处方的关键药物基因对.
科学领域:
- 药物基因组学 药物基因组学
- 儿科药理学 儿科药理学
- 临床遗传学 临床遗传学
背景情况:
- 由于国家卫生系统的更新和指导方针的制定,西班牙的药物遗传学实施加速了.
- 目前的药物遗传学指南和数据主要排除了儿科患者,限制了临床应用.
- 这种差距需要对儿科药物遗传学考虑进行专注的审查.
研究的目的:
- 在西班牙的共同遗传服务组合内审查药物遗传测试.
- 从国家产品特性总结 (SmPC) 和全球/国家指南中分析药物基因信息.
- 提取和评估专门用于儿科的现有药物遗传数据.
主要方法:
- 对遗传服务共同投资组合的系统审查.
- 对药物遗传学建议的产品特征摘要 (SmPC) 的分析.
- 从与儿科有关的主要全球和国家药物遗传学指南中提取和综合信息.
主要成果:
- 确定了具有显著儿科应用的关键药物基因对,包括PPI/CYP2C19,阿巴卡维尔/HLA,沃里科纳/CYP2C19,塔克罗利穆斯/CYP3A5,阿米诺糖化物/MT-RNR1,提奥普林/TMPT/NUDT15,和阿托莫丁/CYP2D6.6.
- 突出了当前指南中关于特定儿科建议的限制.
- 确认了为儿科患者群体提供有针对性的药物遗传信息的需要.
结论:
- 尽管目前存在局限性,但药物遗传学可以在监管机构和科学协会推的儿科护理中实施.
- 进一步的研究和指导方针的制定对于扩大对儿童的药物遗传学使用至关重要.
- 这一审查为将药物遗传学纳入西班牙儿科实践提供了基础.
关键词:
药物遗传学 药物遗传学药物遗传学 药物遗传学精准医学的医学儿科 儿科 儿科儿科医院 (Pediatria) 是一个儿童医院.药物遗传学 药物遗传学药物基因组学 药物基因组学精准医学是一门精准的医学.更多相关视频
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Metabolism
193
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
193
Pharmacokinetics in Pediatric Patients: Drug Distribution
254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
246
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246
Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Drug Dosing: Infants and Children
255
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
255
Dosage Regimens: Partial Pharmacokinetic Parameters
154
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
154


